Orphazyme is pioneering the development of a new type of medical treatment by applying our specialized expertise in heat shock proteins—a key component of the body’s natural cellular stress-defense system. By leveraging the potential of heat shock proteins, such as heat shock protein 70 (HSP70), we are advancing treatments for patients living with a range of neurodegenerative orphan diseases. These diseases can have a devastating impact, and the lack of existing approved treatment options leaves a substantial gap in care today.